Compare Fabrinet (FN) vs Select Medical Holdings Corporation (SEM) Price & Performance

Fabrinet (FN) trades at $460.16, down 4.69% with a bearish technical signal despite strong fundamentals. The company reported consistent earnings beats with Q1 2026 EPS of $3.72 exceeding expectations, driven by 39% YoY revenue growth in optical communications. Analyst consensus remains strongly bullish with 18 buy ratings and a $733 price target, though technical indicators show selling pressure with support at $448.

The outlook remains positive given Fabrinet's strategic position in AI infrastructure and optical communications, with projected revenue growth to $4.2B in 2026. Key risks include premium valuation multiples and supply chain constraints, but the debt-free balance sheet and expanding margins support long-term growth potential in the AI-driven data center market.

Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day. The stock's technical outlook is mixed with a bullish overall signal but bearish moving averages. Fundamentally, the company reported 2025 revenue of $5.45 billion and net income of $146.22 million, with a P/E ratio of 15.43. Recent news highlights the completion of its acquisition by a consortium led by Robert A. Ortenzio and Martin F. for $16.50 per share, finalized on June 30, 2026.

The acquisition at $16.50 per share, slightly below the current price, represents a key near-term catalyst but is under legal scrutiny for potential fiduciary breaches. Analyst sentiment is cautious with a 'Hold' consensus. Risks include integration challenges post-acquisition and margin pressures, with net profit margin declining to 2.41% in 2026. The stock offers limited upside from current levels given the acquisition price cap.